Tumour Lysis Syndrome Risk (Cairo-Bishop)
Diagnosis
Detailed Guide Coming Soon
We're working on a comprehensive educational guide for the Tumour Lysis Syndrome Risk in your language. The content below is shown in English.
Hva er Tumour Lysis Syndrome Risk?
▾
Tumour lysis syndrome (TLS) is a potentially life-threatening oncological emergency resulting from the rapid destruction of cancer cells — either spontaneously or, more commonly, in response to cytotoxic chemotherapy, targeted therapy, or immunotherapy. When tumour cells lyse in large numbers, they release their intracellular contents into the bloodstream simultaneously: potassium, phosphate, and nucleic acids (which are metabolised to uric acid) flood the systemic circulation faster than the kidneys can clear them. The resulting metabolic derangements — hyperuricaemia, hyperkalaemia, hyperphosphataemia, and secondary hypocalcaemia — can cause acute kidney injury, cardiac arrhythmias, seizures, and death. Tumour lysis syndrome is classified using the Cairo-Bishop criteria, which define laboratory TLS (LTLS) as two or more of the following laboratory abnormalities within 3 days before or 7 days after initiation of chemotherapy: serum uric acid above 476 µmol/L (8 mg/dL) or a 25% increase from baseline; serum potassium above 6 mmol/L or 25% increase from baseline; serum phosphate above 1.45 mmol/L (4.5 mg/dL) or 25% increase from baseline; or serum calcium below 1.75 mmol/L (7 mg/dL) or a 25% decrease from baseline. Clinical TLS (CTLS) requires laboratory TLS plus one or more of: creatinine elevation >1.5x ULN, cardiac arrhythmia or sudden death, or seizure. Risk stratification into low, intermediate, and high risk groups guides prophylaxis intensity. High-risk conditions include Burkitt lymphoma, acute lymphoblastic leukaemia (ALL) with blast count above 50 × 10^9/L, bulky lymphoma, AML with hyperleukocytosis, and CLL treated with venetoclax. High-risk patients require rasburicase prophylaxis; intermediate-risk patients receive allopurinol; low-risk patients require monitoring only.
PrimeCalcPro provides professional-grade tools trusted by businesses and academics.
Formel
▾
Cairo-Bishop LTLS: 2+ of: uric acid >476 µmol/L or 25% increase; K+ >6 mmol/L or 25% increase; phosphate >1.45 mmol/L or 25% increase; Ca2+ <1.75 mmol/L or 25% decrease; within 3 days pre or 7 days post chemotherapyVariabelbeskrivelse
▾
| Symbol | Navn | Enhet | Beskrivelse |
|---|---|---|---|
| UA | Serum Uric Acid | µmol/L | End product of purine nucleotide metabolism from lysed cell DNA. Threshold for TLS criterion: >476 µmol/L or ≥25% increase from baseline. |
| K+ | Serum Potassium | mmol/L | The most immediately dangerous TLS electrolyte — hyperkalaemia causes fatal ventricular arrhythmias. Threshold: >6 mmol/L or ≥25% increase. |
| PO4 | Serum Phosphate | mmol/L | Released from intracellular organelles during cell lysis. Binds calcium, causing secondary hypocalcaemia. Threshold: >1.45 mmol/L or ≥25% increase. |
| Ca2+ | Serum Calcium | mmol/L | Falls secondary to hyperphosphataemia-driven calcium-phosphate complex formation. Threshold: <1.75 mmol/L or ≥25% decrease. |
Slik Tumour Lysis Syndrome Risk
▾
- 1Before starting chemotherapy, assess tumour type, bulk, and baseline laboratory values (uric acid, potassium, phosphate, calcium, creatinine, LDH). Classify the patient into low, intermediate, or high TLS risk based on tumour-specific criteria.
- 2Monitor laboratory values every 6–8 hours in high-risk patients from 12–24 hours before chemotherapy through the peak lysis period (usually 24–72 hours after treatment initiation).
- 3Apply Cairo-Bishop laboratory TLS criteria: check for uric acid above 476 µmol/L or ≥25% increase from baseline — this reflects nucleic acid metabolism from lysed cells.
- 4Check for hyperkalaemia: potassium above 6.0 mmol/L or ≥25% increase from baseline. Hyperkalaemia is the most immediately life-threatening TLS abnormality, causing potentially fatal cardiac arrhythmias.
- 5Check for hyperphosphataemia: phosphate above 1.45 mmol/L or ≥25% increase. Phosphate released from lysed cells binds calcium, causing secondary hypocalcaemia.
- 6Check for hypocalcaemia: calcium below 1.75 mmol/L or ≥25% decrease from baseline. Hypocalcaemia causes neuromuscular irritability, tetany, and seizures.
- 7If ≥2 laboratory criteria are met = LTLS. If LTLS plus creatinine >1.5x ULN, arrhythmia, or seizure = CTLS. Initiate or escalate treatment accordingly: hyperhydration, allopurinol (intermediate), rasburicase (high risk or confirmed TLS).
Løste eksempler
▾
Rasburicase mandatory; aggressive IV hyperhydration; cardiac monitoring; ICU consideration
Burkitt lymphoma is the highest-risk tumour for TLS, with rapid cell death from its extreme proliferation rate. Rasburicase, which catabolises uric acid directly, is essential prophylaxis and treatment in this setting.
LTLS confirmed; assess for CTLS (check creatinine, ECG for arrhythmia, neurological status); start rasburicase if not already given
Three Cairo-Bishop criteria are met simultaneously, confirming LTLS. An ECG is immediately required to assess QT prolongation from hypocalcaemia and arrhythmia from hyperkalaemia.
Allopurinol prophylaxis; aggressive oral/IV hydration; 8-hourly electrolyte monitoring for 48–72h post-chemotherapy
DLBCL with bulky disease and elevated LDH is classified as intermediate risk. Allopurinol and hyperhydration are standard prophylaxis. Rasburicase is reserved for breakthrough TLS or high-risk features.
Ensure adequate hydration; routine monitoring; allopurinol may be used as prophylaxis
CLL treated with standard chemoimmunotherapy carries low TLS risk. Note: CLL treated with venetoclax has high TLS risk and requires mandatory dose-ramp-up schedule with prophylaxis.
Praktiske anvendelser
▾
Pre-chemotherapy risk stratification: haematology-oncology teams classify TLS risk for every patient starting new chemotherapy, determining whether prophylaxis with allopurinol, rasburicase, and/or hospitalisation is required., representing an important application area for the Tumour Lysis Risk in professional and analytical contexts where accurate tumour lysis risk calculations directly support informed decision-making, strategic planning, and performance optimization
Venetoclax dose ramp-up protocols: all venetoclax-treated patients follow mandatory weekly dose-escalation schedules with TLS monitoring, prophylaxis, and hospital observation during peak risk periods., representing an important application area for the Tumour Lysis Risk in professional and analytical contexts where accurate tumour lysis risk calculations directly support informed decision-making, strategic planning, and performance optimization
ICU oncology: intensivists managing confirmed TLS guide fluid therapy, renal replacement therapy, and cardiac monitoring based on the specific Cairo-Bishop abnormalities present., representing an important application area for the Tumour Lysis Risk in professional and analytical contexts where accurate tumour lysis risk calculations directly support informed decision-making, strategic planning, and performance optimization
Haematology nursing: oncology nurses perform standardised metabolic panel checks every 6–8 hours during high-TLS-risk treatment periods, applying Cairo-Bishop criteria to trigger early physician escalation., representing an important application area for the Tumour Lysis Risk in professional and analytical contexts where accurate tumour lysis risk calculations directly support informed decision-making, strategic planning, and performance optimization
Rasburicase stewardship: pharmacy-led protocols ensure rasburicase is used appropriately in high-risk and confirmed TLS cases (not routinely for all neutropenic patients), given its high cost and G6PD contraindication., representing an important application area for the Tumour Lysis Risk in professional and analytical contexts where accurate tumour lysis risk calculations directly support informed decision-making, strategic planning, and performance optimization
Spesielle tilfeller
▾
Rasburicase in G6PD deficiency
In the Tumour Lysis Risk, this scenario requires additional caution when interpreting tumour lysis risk results. The standard formula may not fully account for all factors present in this edge case, and supplementary analysis or expert consultation may be warranted. Professional best practice involves documenting assumptions, running sensitivity analyses, and cross-referencing results with alternative methods when tumour lysis risk calculations fall into non-standard territory.
Allopurinol blood sample interference
{'title': 'Allopurinol blood sample interference', 'body': 'Rasburicase degrades uric acid ex vivo in blood samples at room temperature. Blood drawn from patients receiving rasburicase must be collected in pre-chilled EDTA tubes and placed immediately on ice, then processed within 4 hours, to prevent falsely low uric acid results that would mask true hyperuricaemia.'}
Urinary alkalinisation — no longer routinely recommended
{'title': 'Urinary alkalinisation — no longer routinely recommended', 'body': 'Urinary alkalinisation with sodium bicarbonate was historically used to increase uric acid solubility in urine. However, alkalinisation promotes calcium-phosphate precipitation in tubules, potentially worsening hypocalcaemia and AKI. Current guidelines do not recommend routine urinary alkalinisation; hyperhydration with normal saline is the preferred approach.'}
TLS in solid tumours after immunotherapy
{'title': 'TLS in solid tumours after immunotherapy', 'body': 'TLS has been increasingly reported with immune checkpoint inhibitors and targeted agents (including BCL-2 inhibitors and CAR-T cell therapy) in solid tumours — conditions previously considered very low risk. Clinicians prescribing novel agents should be aware of emerging TLS risk profiles outside traditional haematological malignancies.'}
Cairo-Bishop TLS Criteria and Risk Stratification
▾
| Parameter | LTLS Criterion | Clinical TLS Criterion |
|---|---|---|
| Uric acid | > 476 µmol/L (8 mg/dL) or ≥25% increase | — |
| Potassium | > 6.0 mmol/L or ≥25% increase | Arrhythmia or sudden death |
| Phosphate | > 1.45 mmol/L (4.5 mg/dL) or ≥25% increase | — |
| Calcium | < 1.75 mmol/L (7 mg/dL) or ≥25% decrease | Seizure |
| Creatinine | — | > 1.5x upper limit of normal |
| Definition | 2+ criteria within 3 days pre or 7 days post chemo | LTLS + creatinine, arrhythmia, or seizure |
| High risk | Burkitt lymphoma, ALL >50×10^9/L blasts, AML hyperleukocytosis, venetoclax-CLL | Rasburicase mandatory |
| Intermediate risk | Bulky DLBCL, ALL lower burden, AML WBC 10–100×10^9/L | Allopurinol + hyperhydration |
| Low risk | Solid tumours, CLL standard therapy, indolent lymphoma | Hydration + monitoring |
Ofte stilte spørsmål
▾
What is tumour lysis syndrome?
Tumour lysis syndrome is a metabolic emergency caused by massive rapid destruction of cancer cells, releasing intracellular potassium, phosphate, and nucleic acids into the bloodstream. The resulting hyperuricaemia, hyperkalaemia, hyperphosphataemia, and secondary hypocalcaemia can cause acute kidney injury, cardiac arrhythmias, seizures, and death without prompt treatment. This is particularly important in the context of tumour lysis risk calculations, where accuracy directly impacts decision-making. Professionals across multiple industries rely on precise tumour lysis risk computations to validate assumptions, optimize processes, and ensure compliance with applicable standards. Understanding the underlying methodology helps users interpret results correctly and identify when additional analysis may be warranted.
Which cancers are at highest risk for TLS?
The highest-risk cancers for TLS are Burkitt lymphoma (the highest), ALL with blast count above 50 × 10^9/L, AML with hyperleukocytosis, bulky diffuse large B-cell lymphoma, and CLL treated with venetoclax. The combination of rapid tumour doubling time, high sensitivity to chemotherapy, and large tumour bulk creates extreme lysis risk.
What is the difference between laboratory TLS and clinical TLS?
Laboratory TLS (LTLS) is defined by two or more Cairo-Bishop metabolic abnormalities (uric acid, potassium, phosphate, or calcium) occurring within the defined time window. Clinical TLS (CTLS) requires LTLS plus at least one clinical consequence: creatinine elevation above 1.5x ULN, cardiac arrhythmia or sudden death, or seizure. CTLS carries significantly higher mortality than LTLS alone.
What is rasburicase and when is it used?
Rasburicase is a recombinant urate oxidase enzyme that catabolises uric acid to allantoin, which is 5–10 times more soluble and readily excreted by the kidneys. Unlike allopurinol (which prevents new uric acid formation), rasburicase actively degrades existing uric acid and works within hours. It is used for high-risk TLS prophylaxis and treatment of confirmed TLS with hyperuricaemia.
What is venetoclax ramp-up and why is it required?
Venetoclax (a BCL-2 inhibitor used in CLL and AML) has a very high TLS risk because it is extremely effective at inducing rapid tumour cell apoptosis. All patients starting venetoclax undergo a mandatory weekly dose-escalation schedule over 5 weeks, with TLS prophylaxis (allopurinol or rasburicase based on risk), intensive monitoring, and in some cases hospitalisation during the highest-risk first-cycle period.
Why does TLS cause low calcium?
Hyperphosphataemia from cell lysis leads to the precipitation of calcium-phosphate complexes in tissues and in the bloodstream. This binds free ionised calcium, reducing its concentration. Hypocalcaemia causes neuromuscular irritability, carpopedal spasm, tetany, and in severe cases seizures and life-threatening cardiac arrhythmias. This is particularly important in the context of tumour lysis risk calculations, where accuracy directly impacts decision-making. Professionals across multiple industries rely on precise tumour lysis risk computations to validate assumptions, optimize processes, and ensure compliance with applicable standards. Understanding the underlying methodology helps users interpret results correctly and identify when additional analysis may be warranted.
Is spontaneous TLS possible without chemotherapy?
Yes. Spontaneous TLS is rare but occurs in highly proliferative tumours (particularly Burkitt lymphoma and some ALL cases) before any treatment has been given. It represents such rapid natural cell turnover that lysis outpaces renal clearance. Patients presenting with Burkitt lymphoma who have not yet received chemotherapy may already have laboratory TLS on initial assessment.
How does hyperhydration help prevent TLS?
Aggressive intravenous hyperhydration (typically 2–3 litres/m²/day to maintain urine output above 80–100 mL/hour) dilutes and enhances renal clearance of uric acid, potassium, and phosphate released by lysing tumour cells. Adequate hydration is the cornerstone of TLS prophylaxis and must begin 24–48 hours before chemotherapy in high-risk patients. This is particularly important in the context of tumour lysis risk calculations, where accuracy directly impacts decision-making. Professionals across multiple industries rely on precise tumour lysis risk computations to validate assumptions, optimize processes, and ensure compliance with applicable standards. Understanding the underlying methodology helps users interpret results correctly and identify when additional analysis may be warranted.
Vanlige feil å unngå
▾
- !Using mg/dL thresholds when laboratory reports are in mmol/L without converting (uric acid: divide mg/dL by 0.059 to get µmol/L; phosphate: multiply mg/dL by 0.323 to get mmol/L).
- !Not accounting for the 3-day pre-chemotherapy window in the Cairo-Bishop criteria — TLS can occur before the first chemotherapy dose in highly proliferative spontaneous disease.
- !Forgetting to screen for G6PD deficiency before prescribing rasburicase, risking severe haemolysis in a population that includes patients of African, Mediterranean, or Asian descent.
- !Collecting uric acid samples at room temperature in rasburicase-treated patients — ex vivo degradation of uric acid will produce falsely normal results, masking persistent hyperuricaemia.
- !Using urinary alkalinisation with sodium bicarbonate in hyperphosphataemic patients — calcium-phosphate precipitation worsens AKI and hypocalcaemia in this setting.
- !Classifying CLL as low-risk without checking whether venetoclax is involved — venetoclax-treated CLL is one of the highest-risk TLS scenarios and requires the full high-risk prophylaxis protocol with mandatory dose ramp-up.
Pro Tips
For any patient with a highly proliferative haematological malignancy, check serum uric acid, potassium, phosphate, calcium, creatinine, and LDH BEFORE starting chemotherapy. Spontaneous laboratory TLS may already be present at diagnosis, particularly in Burkitt lymphoma and hyperleukocytic AML, and will change your management plan before you have administered a single chemotherapy dose.
Visste du?
Burkitt lymphoma has the fastest doubling time of any human tumour — under ideal conditions it can double its cell mass in as little as 24 hours. This extraordinary proliferation rate also means it releases enormous quantities of cellular contents when killed by chemotherapy, making TLS virtually universal without prophylaxis. Paradoxically, its high curability with modern chemotherapy means the treatment itself creates the greatest immediate mortality risk.
Regional Guides
▾
🇺🇸 US▾
🇬🇧 UK▾
🇪🇺 EU▾
Referanser
- ›Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004.
- ›Howard SC et al. The Tumor Lysis Syndrome. NEJM 2011.
- ›Coiffier B et al. Guidelines for the management of pediatric and adult tumor lysis syndrome. J Clin Oncol 2008.
- ›Roberts AW et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. NEJM 2016.
- ›MDCalc — Tumour Lysis Syndrome: Cairo-Bishop Classification
Have a question about this calculator? Get a detailed answer.
Read the full guide on how to use this calculator effectively
Les mer →Få ukentlige mattetips
Bli med 12 000+-abonnenter som får kalkulatortips hver uke.